论文部分内容阅读
CD137是近年新发现的肿瘤坏死因子受体超家族的新成员 ,是一种新的共刺激信号分子。它参与T细胞的活化、分化、增殖、凋亡、信号传导及细胞外粘附 ;活化的CD137参与调节细胞因子对粒细胞的抗凋亡作用 ;CD137作为一个独特的潜在的单核细胞存活因子 ,可诱导单核细胞存活、增殖与粘附 ;CD137作为一种重要的受体亦参与调节树突状细胞 (DC)的功能 ;CD137的配体 (CD137L)表达于癌细胞表面 ,在肿瘤免疫及治疗中起作用 ;自身免疫病中慢性活化的自身反应T细胞表达CD137,CD137的异常表达与免疫疾病的发生存在某种关系 ;CD137在改善骨髓移植后异源T细胞的移植物抗宿主病 (GVHD)和移植物抗白血病 (GVL)等异源免疫反应中亦起重要作用。
CD137 is a new member of newly discovered tumor necrosis factor receptor superfamily in recent years and is a new co-stimulatory signaling molecule. It is involved in the activation, differentiation, proliferation, apoptosis, signal transduction and extracellular adhesion of T cells. Activating CD137 is involved in the regulation of anti-apoptotic effect of cytokines on granulocytes. CD137 acts as a unique potential monocyte survival factor , Which can induce the survival, proliferation and adhesion of monocytes. CD137 also participates in the regulation of dendritic cells (DC) as an important receptor. The CD137 ligand (CD137L) is expressed on the surface of cancer cells. And treatment; autoimmune disease chronic activation of autoreactive T cells express CD137, CD137 abnormal expression and the occurrence of immune diseases there is a relationship; CD137 in improving allogeneic T cell transplantation after bone marrow graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL).